Why Purple Biotech (PPBT) Stock Is Getting Hammered
Why Purple Biotech (PPBT) Stock Is Getting Hammered
The company anticipates gross proceeds of approximately $2.8 million, which will support the development of its oncology therapies and general corporate needs. Purple Biotech says the company is meanwhile focused on innovative treatments addressing tumor immune evasion and drug resistance.Purple Biotech Ltd – ADR (NASDAQ:PPBT) shares are trading lower by 27.7% to $6.02 during Tuesday's session after the company announced a $2.8 million offering of 472,688 ADS.
紫色生物技術有限公司 - ADR（納斯達克：PPBT）股票在週二交易會話中下跌了27.7%，至6.02美元，此前該公司宣佈以280萬美元的價格出售472,688股ADS。
The stock is also pulling back after the company's Phase 2 trial of CM24 combined with nivolumab and standard chemotherapy for metastatic pancreatic cancer showed significantly improved survival, response rates and biomarker reductions compared to standard care, with a favorable safety profile.
該公司的CM24與尼伏單抗和標準化療聯合用於轉移性胰腺癌的2期臨床試驗顯示，與標準治療相比，明顯改善了生存率、應答率和生物標誌物減少，並具有有利的安全性。股票也在獲悉該消息後回調。
What Else: Purple Biotech entered a definitive agreement to sell 472,668 American Depositary Shares (ADSs) at $6.00 per ADS in a registered direct offering. The offering, led by H.C. Wainwright & Co., is expected to close on December 4, subject to customary conditions.
此外：紫色生物技術達成一項最終協議，以每股6.00美元的價格出售472,668美國存托股份（ADS）進行註冊直接發行。該次發行由H.C.韋恩萊特＆Co.領導，預計將於12月4日收盤，視情況而定。
The company anticipates gross proceeds of approximately $2.8 million, which will support the development of its oncology therapies and general corporate needs. Purple Biotech says the company is meanwhile focused on innovative treatments addressing tumor immune evasion and drug resistance.
公司預計募集約280萬美元的總收入，將用於支持其腫瘤學治療和一般公司需求的發展。紫色生物技術表示公司同時專注於創新治療，以應對腫瘤免疫逃避和藥物耐藥問題。
Read Also: Why Cheetah Net Supply Chain Service (CTNT) Stock Is Up 270%
閱讀更多：爲什麼獵豹淨供應鏈服務（CTNT）股票上漲270%
Should I Sell My PPBT Stock?
我應該賣出我的PPBt股票嗎？
When deciding to hold on to or sell a stock, investors should consider their time horizon, unrealized gains and total return.
在決定持有或出售股票時，投資者應考慮他們的投資期限、未實現收益和總回報。
Shares of Purple Biotech have decreased by 60.75% in the past year. An investor who bought shares of Purple Biotech at the beginning of the year would take a loss of $7.01 per share if they sold it today. The stock has risen 182.83% over the past month, meaning an investor who bought shares on Nov. 1 would see a capital gain of $5.43.
紫色生物技術的股票在過去一年中下跌了60.75%。一位在年初購買紫色生物技術股票的投資者，如果今天賣出，每股將虧損7.01美元。股價在過去一個月上漲了182.83%，這意味着在11月1日購買股票的投資者將看到5.43美元的資本收益。
For access to advanced charting and analysis tools and stock data, check out Benzinga PRO. Try it for free.
獲取先進的圖表和分析工具以及股票數據，請查看Benzinga PRO。免費試用。
PPBT has a 52-week high of $23.20 and a 52-week low of $2.00.
PPBt的52周最高價爲$23.20，52周最低價爲$2.00。
譯文內容由第三人軟體翻譯。
